TP53BP1 and breast carcinoma: This agrees with studies in ATM-deficient breast cancer cells showing that 53BP1 depletion causes PARPi resistance [47], but is at odds with the demonstration that loss of 53BP1 cannot suppress the PARPi sensitivity of Atm-/- mESCs [63].